Malik, Z.; Di Lorenzo, G.; Pichler, A.; De Giorgi, U.; Hitier, S.; Ecstein-Fraisse, E.; Ozatilgan, A.; Carles, J.
Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry. Cancers 2020, 12, 995.
https://doi.org/10.3390/cancers12040995
AMA Style
Malik Z, Di Lorenzo G, Pichler A, De Giorgi U, Hitier S, Ecstein-Fraisse E, Ozatilgan A, Carles J.
Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry. Cancers. 2020; 12(4):995.
https://doi.org/10.3390/cancers12040995
Chicago/Turabian Style
Malik, Zafar, Giuseppe Di Lorenzo, Angelika Pichler, Ugo De Giorgi, Simon Hitier, Evelyne Ecstein-Fraisse, Ayse Ozatilgan, and Joan Carles.
2020. "Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry" Cancers 12, no. 4: 995.
https://doi.org/10.3390/cancers12040995
APA Style
Malik, Z., Di Lorenzo, G., Pichler, A., De Giorgi, U., Hitier, S., Ecstein-Fraisse, E., Ozatilgan, A., & Carles, J.
(2020). Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry. Cancers, 12(4), 995.
https://doi.org/10.3390/cancers12040995